SI4320112T1 - Oksoizoindolin spojine, substituirane s piridinilom - Google Patents
Oksoizoindolin spojine, substituirane s piridinilomInfo
- Publication number
- SI4320112T1 SI4320112T1 SI202230144T SI202230144T SI4320112T1 SI 4320112 T1 SI4320112 T1 SI 4320112T1 SI 202230144 T SI202230144 T SI 202230144T SI 202230144 T SI202230144 T SI 202230144T SI 4320112 T1 SI4320112 T1 SI 4320112T1
- Authority
- SI
- Slovenia
- Prior art keywords
- oxoisoindoline
- compounds
- pyridinyl substituted
- pyridinyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| EP22718513.9A EP4320112B1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4320112T1 true SI4320112T1 (sl) | 2025-09-30 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202230144T SI4320112T1 (sl) | 2021-04-06 | 2022-04-05 | Oksoizoindolin spojine, substituirane s piridinilom |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11718601B2 (sl) |
| EP (1) | EP4320112B1 (sl) |
| JP (1) | JP2024515243A (sl) |
| KR (1) | KR20230165815A (sl) |
| AR (1) | AR125298A1 (sl) |
| AU (1) | AU2022253242A1 (sl) |
| BR (1) | BR112023020077A2 (sl) |
| CA (1) | CA3214244A1 (sl) |
| CL (1) | CL2023002966A1 (sl) |
| CO (1) | CO2023013321A2 (sl) |
| DK (1) | DK4320112T3 (sl) |
| ES (1) | ES3035755T3 (sl) |
| FI (1) | FI4320112T3 (sl) |
| HR (1) | HRP20250796T1 (sl) |
| HU (1) | HUE072309T2 (sl) |
| IL (1) | IL307343A (sl) |
| LT (1) | LT4320112T (sl) |
| MX (1) | MX2023011715A (sl) |
| PE (1) | PE20231941A1 (sl) |
| PL (1) | PL4320112T3 (sl) |
| PT (1) | PT4320112T (sl) |
| RS (1) | RS66982B1 (sl) |
| SI (1) | SI4320112T1 (sl) |
| SM (1) | SMT202500281T1 (sl) |
| TW (1) | TWI867287B (sl) |
| WO (1) | WO2022216644A1 (sl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| CN120677149A (zh) * | 2023-02-08 | 2025-09-19 | 细胞基因公司 | 用于选择性降解工程化蛋白的化合物和组合物 |
| AR133696A1 (es) | 2023-09-02 | 2025-10-22 | Bristol Myers Squibb Co | Compuestos de fenil oxooxazolil piperidinadiona sustituida |
| WO2025199379A1 (en) | 2024-03-22 | 2025-09-25 | Bristol-Myers Squibb Company | Novel fak degrader compounds and uses thereof |
| WO2025226767A1 (en) * | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2025234888A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025234887A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| ATE428419T1 (de) | 2001-08-06 | 2009-05-15 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| ME02461B (me) | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| PT2949670T (pt) | 2009-12-10 | 2019-05-20 | Hoffmann La Roche | Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização |
| NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CN107011438B (zh) | 2010-05-04 | 2020-11-20 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (sl) | 2011-04-15 | 2018-03-17 | ||
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AU2012374617B2 (en) | 2012-05-11 | 2015-09-17 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| JP6629885B2 (ja) | 2015-05-22 | 2020-01-15 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物、その組成物、方法、および使用 |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| US11395820B2 (en) | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| EP3445764B1 (en) | 2016-04-22 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3512855B1 (en) | 2016-09-13 | 2022-07-27 | The Regents of the University of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| CA3038979A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| RS64976B1 (sr) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora |
| CN110099907A (zh) | 2016-12-21 | 2019-08-06 | 拜欧赛里克斯公司 | 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途 |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| JP7679173B2 (ja) | 2016-12-23 | 2025-05-19 | アルビナス・オペレーションズ・インコーポレイテッド | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| CA3079407A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| JP2021519337A (ja) * | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN112601751B (zh) | 2018-06-13 | 2024-04-02 | 拜欧斯瑞克斯公司 | 稠合噻吩化合物 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| PL3820573T3 (pl) | 2018-07-10 | 2024-02-19 | Novartis Ag | Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2) |
| EP3880669A1 (en) * | 2018-11-13 | 2021-09-22 | Biotheryx, Inc. | Substituted isoindolinones |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| EP3924055B1 (en) * | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7483732B2 (ja) * | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US20230093099A1 (en) | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 PL PL22718513.9T patent/PL4320112T3/pl unknown
- 2022-04-05 DK DK22718513.9T patent/DK4320112T3/da active
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko active Pending
- 2022-04-05 PT PT227185139T patent/PT4320112T/pt unknown
- 2022-04-05 EP EP22718513.9A patent/EP4320112B1/en active Active
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
- 2022-04-05 JP JP2023561684A patent/JP2024515243A/ja active Pending
- 2022-04-05 MX MX2023011715A patent/MX2023011715A/es unknown
- 2022-04-05 FI FIEP22718513.9T patent/FI4320112T3/fi active
- 2022-04-05 SI SI202230144T patent/SI4320112T1/sl unknown
- 2022-04-05 ES ES22718513T patent/ES3035755T3/es active Active
- 2022-04-05 SM SM20250281T patent/SMT202500281T1/it unknown
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en not_active Ceased
- 2022-04-05 TW TW111112957A patent/TWI867287B/zh active
- 2022-04-05 LT LTEPPCT/US2022/023387T patent/LT4320112T/lt unknown
- 2022-04-05 RS RS20250660A patent/RS66982B1/sr unknown
- 2022-04-05 HU HUE22718513A patent/HUE072309T2/hu unknown
- 2022-04-05 HR HRP20250796TT patent/HRP20250796T1/hr unknown
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en not_active Abandoned
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
-
2024
- 2024-06-25 US US18/740,857 patent/US20240376082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT4320112T (lt) | 2025-07-10 |
| US20230303527A1 (en) | 2023-09-28 |
| PE20231941A1 (es) | 2023-12-05 |
| WO2022216644A1 (en) | 2022-10-13 |
| EP4320112A1 (en) | 2024-02-14 |
| DK4320112T3 (da) | 2025-08-18 |
| JP2024515243A (ja) | 2024-04-08 |
| EP4320112B1 (en) | 2025-05-14 |
| TW202304881A (zh) | 2023-02-01 |
| CA3214244A1 (en) | 2022-10-13 |
| PT4320112T (pt) | 2025-07-07 |
| RS66982B1 (sr) | 2025-07-31 |
| US20220324840A1 (en) | 2022-10-13 |
| US11718601B2 (en) | 2023-08-08 |
| IL307343A (en) | 2023-11-01 |
| CL2023002966A1 (es) | 2024-02-23 |
| FI4320112T3 (fi) | 2025-07-25 |
| MX2023011715A (es) | 2023-10-12 |
| AR125298A1 (es) | 2023-07-05 |
| SMT202500281T1 (it) | 2025-09-12 |
| HRP20250796T1 (hr) | 2025-08-29 |
| HUE072309T2 (hu) | 2025-11-28 |
| KR20230165815A (ko) | 2023-12-05 |
| PL4320112T3 (pl) | 2025-07-21 |
| AU2022253242A1 (en) | 2023-11-23 |
| BR112023020077A2 (pt) | 2023-11-14 |
| US20240376082A1 (en) | 2024-11-14 |
| TWI867287B (zh) | 2024-12-21 |
| ES3035755T3 (en) | 2025-09-08 |
| CO2023013321A2 (es) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE072309T2 (hu) | Piridinilszubsztituált oxoizoindolin vegyületek | |
| EP4452937A4 (en) | CONNECTIONS | |
| GB202016614D0 (en) | Compounds | |
| GB202013558D0 (en) | GRP52 Modularor compounds | |
| GB202020047D0 (en) | Compounds | |
| GB202017406D0 (en) | Compounds | |
| GB202016977D0 (en) | Compounds | |
| GB202014944D0 (en) | Compounds | |
| GB202011811D0 (en) | Compounds | |
| GB202011812D0 (en) | Compounds | |
| GB202001564D0 (en) | Compounds | |
| HK40103406A (zh) | 吡啶基取代的氧代异吲哚啉化合物 | |
| GB202102709D0 (en) | Compounds | |
| GB202100645D0 (en) | Compounds | |
| GB202020370D0 (en) | Compounds | |
| GB202019427D0 (en) | Compounds | |
| GB202019429D0 (en) | Compounds | |
| GB202019428D0 (en) | Compounds | |
| GB202018034D0 (en) | Compounds | |
| GB202017630D0 (en) | Compounds | |
| GB202016245D0 (en) | Compounds | |
| GB202014255D0 (en) | Compounds | |
| GB202012802D0 (en) | Compounds | |
| GB202011924D0 (en) | Compounds | |
| GB202011537D0 (en) | Compounds |